{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:34:40Z","timestamp":1785180880958,"version":"3.55.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Infections caused by multidrug-resistant (MDR) bacteria are a major public health threat. We aimed to assess the data supporting US Food and Drug Administration (FDA) approval of new agents aimed to treat MDR bacterial infections and the data provided by postmarketing studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified all drugs with in vitro activity against MDR bacteria initially approved by the FDA between January 2010 and December 2018. Characteristics of trials supporting approval and regulatory pathways were collected from Drugs@FDA. Characteristics of postmarketing studies were extracted from drug labels and ClinicalTrials.gov entries effective 1 June 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Initial approval of 11 newly approved antibiotics with anti-MDR activity was supported by 20 trials, all with noninferiority design. All initially approved indications were for common infections, mostly acute bacterial skin and skin-structure infections, regardless of causative microorganism. The proportion of MDR bacteria in most trials was low (&amp;lt;10% for gram-negative infections, &amp;lt;1% for gram-positive pneumonia). Most trials (90%) excluded immunocompromised and critically ill patients. Of 16 additional postmarketing randomized controlled trials identified through ClinicalTrials.gov, only 2 exclusively included infections caused by MDR bacteria, comprising 116 patients. No drug was granted accelerated approval, which would mandate postmarketing efficacy studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The approval of new drugs with potential clinical activity against MDR bacteria is supported by trials evaluating infections caused by non-MDR organisms, using noninferiority design and excluding the patients most likely to require these agents. Subsequent postmarketing efficacy data against these organisms are scarce. Healthcare professionals and regulators should demand more robust data to support clinical decision making.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa457","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T19:11:24Z","timestamp":1587150684000},"page":"1968-1974","source":"Crossref","is-referenced-by-count":27,"title":["Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria"],"prefix":"10.1093","volume":"72","author":[{"given":"Dafna","family":"Yahav","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Tau","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Tel Aviv, Israel"},{"name":"Department of Diagnostic Imaging, Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shepshelovich","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Tel Aviv, Israel"},{"name":"Medicine I, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"2021060106101912900_CIT0001","author":"Centers for Disease Control and Prevention"},{"key":"2021060106101912900_CIT0002","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 x \u201820 Progress\u2014development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0003","year":"2015"},{"key":"2021060106101912900_CIT0004","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/jac\/dkv020","article-title":"Antibiotic research and development: business as usual?","volume":"70","author":"Harbarth","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0005"},{"key":"2021060106101912900_CIT0006","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1016\/S1473-3099(19)30284-1","article-title":"Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials","volume":"19","author":"Lanini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021060106101912900_CIT0007"},{"key":"2021060106101912900_CIT0008","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021060106101912900_CIT0009","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","article-title":"Analysis of the clinical antibacterial and antituberculosis pipeline","volume":"19","author":"Theuretzbacher","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021060106101912900_CIT0010","year":"2020"},{"key":"2021060106101912900_CIT0011","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0012","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0013","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0014","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0015","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2021060106101912900_CIT0016","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0017","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0018","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2021060106101912900_CIT0019","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2021060106101912900_CIT0020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","volume":"71","author":"Kingsley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021060106101912900_CIT0021","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0022","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2021060106101912900_CIT0023","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0024","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2021060106101912900_CIT0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2021060106101912900_CIT0026","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2021060106101912900_CIT0027","article-title":"A phase 3 randomized, double-blind, multi-center study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 Study) [Poster 64].","volume-title":"ESCMID\/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance","author":"O\u2019Riordan","year":"2018"},{"key":"2021060106101912900_CIT0028","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"2021060106101912900_CIT0029","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2021060106101912900_CIT0031","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2021060106101912900_CIT0032","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"2021060106101912900_CIT0033"},{"key":"2021060106101912900_CIT0034","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2021060106101912900_CIT0035","doi-asserted-by":"crossref","first-page":"k587","DOI":"10.1136\/bmj.k587","article-title":"Studying new antibiotics for multidrug resistant infections: are today\u2019s patients paying for unproved future benefits?","volume":"360","author":"Powers","year":"2018","journal-title":"BMJ"},{"key":"2021060106101912900_CIT0036","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/19466315.2014.1002627","article-title":"A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect","volume":"7","author":"Odem-Davis","year":"2015","journal-title":"Stat Biopharm Res"},{"key":"2021060106101912900_CIT0037","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamainternmed.2018.7040","article-title":"Communication of nonefficacy benefits of new drugs approved on the basis of noninferiority trials alone: cohort study of FDA and sponsor communication, 2011\u20132017","volume":"179","author":"Doshi","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2021060106101912900_CIT0038","first-page":"377","article-title":"Reporting of drug","volume":"; 35:","author":"Desai","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2021060106101912900_CIT0039","article-title":"US Food and Drug Administration recommendations on the use of surrogate measures as end points in new anti-infective drug approvals","author":"Hey","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2021060106101912900_CIT0040","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijantimicag.2018.06.018","article-title":"Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"52","author":"Russo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021060106101912900_CIT0041","author":"Center for Drug Evaluation and Research","year":"2019"},{"key":"2021060106101912900_CIT0042","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0043","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/cis688","article-title":"White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens","volume":"55","author":"Infectious Diseases Society of America","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021060106101912900_CIT0044","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamaoncol.2019.0093","article-title":"US food and drug administration approval of new drugs based on noninferiority trials in oncology: a dangerous precedent?","volume":"5","author":"Gyawali","year":"2019","journal-title":"JAMA Oncol"},{"key":"2021060106101912900_CIT0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/M16-0291","article-title":"Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010\u20132015","volume":"165","author":"Deak","year":"2016","journal-title":"Ann Intern Med"},{"key":"2021060106101912900_CIT0046","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for gram-positive bacteria","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa457\/33462951\/ciaa457.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/1968\/38389239\/ciaa457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/11\/1968\/38389239\/ciaa457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T17:05:23Z","timestamp":1666371923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/11\/1968\/5825522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,4,27]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa457","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,4,27]]}}}